Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for HALO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2002. Start Trial.
Date Value
June 30, 2026 327.86M
March 31, 2026 0.00
December 31, 2025 -4.146M
September 30, 2025 22.40M
June 30, 2025 302.29M
March 31, 2025 0.00
December 31, 2024 246.42M
September 30, 2024 -18.56M
June 30, 2024 -8.993M
March 31, 2024 0.00
December 31, 2023 249.92M
September 30, 2023 -4.101M
June 30, 2023 -2.446M
March 31, 2023 151.13M
December 31, 2022 -6.968M
September 30, 2022 197.36M
June 30, 2022 -3.821M
March 31, 2022 -0.624M
December 31, 2021 156.01M
September 30, 2021 60.07M
June 30, 2021 44.66M
March 31, 2021 76.78M
December 31, 2020 27.40M
September 30, 2020 43.85M
June 30, 2020 -16.39M
Date Value
March 31, 2020 31.86M
December 31, 2019 191.87M
September 30, 2019 -2.075M
June 30, 2019 -4.467M
March 31, 2019 0.449M
December 31, 2018 -2.063M
September 30, 2018 -3.538M
June 30, 2018 -3.141M
March 31, 2018 -4.977M
December 31, 2017 -5.089M
September 30, 2017 -3.705M
June 30, 2017 -138.46M
March 31, 2017 -0.393M
December 31, 2016 -0.243M
September 30, 2016 -0.511M
June 30, 2016 -0.826M
March 31, 2016 -0.285M
December 31, 2015 -1.731M
September 30, 2015 -0.437M
June 30, 2015 -3.773M
March 31, 2015 -7.157M
December 31, 2014 -2.471M
September 30, 2014 0.137M
June 30, 2014 -1.28M
March 31, 2014 -110.89M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Incyte Corp. -75.15M
AVITA Medical, Inc. -0.4413M
Neurocrine Biosciences, Inc. -128.50M
Iovance Biotherapeutics, Inc. -50.45M
Editas Medicine, Inc. -117.54M